| Literature DB >> 31991659 |
Samuel Bernardo-Bermejo1, Elena Sánchez-López1,2, María Castro-Puyana1,2, Selma Benito-Martínez3,4, Francisco Javier Lucio-Cazaña3, María Luisa Marina1,2.
Abstract
Diabetic nephropathy is characterized by the chronic loss of kidney function due to high glucose renal levels. HK-2 proximal tubular cells are good candidates to study this disease. The aim of this work was to study an in vitro model of high glucose-induced metabolic alterations in HK-2 cells to contribute to the pathogenesis of this diabetic complication. An untargeted metabolomics strategy based on CE-MS was developed to find metabolites affected under high glucose conditions. Intracellular and extracellular fluids from HK-2 cells treated with 25 mM glucose (high glucose group), with 5.5 mM glucose (normal glucose group), and with 5.5 mM glucose and 19.5 mM mannitol (osmotic control group) were analyzed. The main changes induced by high glucose were found in the extracellular medium where increased levels of four amino acids were detected. Three of them (alanine, proline, and glutamic acid) were exported from HK-2 cells to the extracellular medium. Other affected metabolites include Amadori products and cysteine, which are more likely cause and consequence, respectively, of the oxidative stress induced by high glucose in HK-2 cells. The developed CE-MS platform provides valuable insight into high glucose-induced metabolic alterations in proximal tubular cells and allows identifying discriminative molecules of diabetic nephropathy.Entities:
Keywords: capillary electrophoresis-mass spectrometry; diabetic nephropathy; human proximal tubular HK-2 cells; metabolomics; multivariate analysis
Year: 2020 PMID: 31991659 PMCID: PMC7037647 DOI: 10.3390/molecules25030512
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1PCA including QC and excluding QC for the two analytical sequences: (A) intracellular fluid (including QC), (B) extracellular fluid (including QC), (C) intracellular fluid (excluding QC), and (D) extracellular fluid (excluding QC). QC, quality control. NG, normal glucose. HG, high glucose. M, osmotic control.
R2X, R2Y, and Q2 parameters and the F and p-values of the cross validated ANOVA (CV-ANOVA) for the PLS-DA models for the two analytical sequences.
| PLS-DA Models | R2X | R2Y | Q2 | CV-ANOVA | |
|---|---|---|---|---|---|
|
| |||||
| HG vs. NG | 0.801 | 0.985 | 0.933 | F(22.5) | p(2.3 × 10−9) |
| NG vs. M | 0.827 | 0.872 | 0.771 | F(15.8) | p(7.7 × 10−8) |
|
| |||||
| HG vs. NG | 0.670 | 0.993 | 0.974 | F(149.2) | p(8.7 × 10−18) |
| NG vs. M | 0.457 | 0.728 | 0.336 | F(3.1) | p(3.3 × 10−2) |
Figure 2Permutation tests of PLS-DA models of both intracellular and extracellular fluids: (A) intracellular fluid (HG vs. NG), (B) extracellular fluid (HG vs. NG), (C) intracellular fluid (NG vs. M), (D) extracellular fluid (NG vs. M).
Metabolites identified in the intracellular and extracellular analysis by the CE-MS metabolomics platform.
| # | MT (min) | Molecular Formula | Identification | [M] Monoisotopic Mass (Da) | Mass Error (ppm) | Main Fragments (MS/MS) | Trend *** | ||
|---|---|---|---|---|---|---|---|---|---|
| HG vs. NG | NG vs. M | ||||||||
|
| |||||||||
| 1 | 9.7 | C6H14N4O2 | Arginine * | 174.1116 | 0.6 | 130.0975 ([M + H-NH3-CO]+) | 1.33 × 10−2 | 3.53 ×∙10−5 |
|
| 116.0702 ([M + H-CH5N3]+ | |||||||||
| 112.0873 ([M + H-NH3-H2O-CO]+) | |||||||||
| 158.0950 ([M + H-NH3]+) | |||||||||
| 2 | 13.5 | C5H9NO4 | Glutamic acid * | 147.0531 | 0.7 | 84.0446 ([M + H-2H2O-CO]+) | 7.85 ×∙10−8 | 3.81 ×∙10−6 | ↓ |
| 56.0497 ([M + H-2H2O-2CO]+) | |||||||||
| 3 | 23.8 | C5H7NO3 | Pyroglutamic acid * | 129.0424 | 1.5 | 56.0493 ([M + H-H2O-2CO]+) | 5.49∙× 10−3 | 2.90∙× 10−3 | ↑ |
| 84.0443 ([M + H-H2O-CO] +) | |||||||||
|
| |||||||||
| 4 | 12.9 | C6H9N3O2 | Histidine * | 155.0696 | 0.6 | 110.0713 ([M + H-H2O-CO]+) | 1.20∙× 10−2 | 0.79 | ↑ |
| 83.0602 ([M + H-H2O-CO-HCN]+) | |||||||||
| 93.0444 ([M + H-H2O-CO-NH3]+) | |||||||||
| 5 | 15.8 | C3H7NO2 | Alanine * | 89.0476 | 0.9 | 58.0619 | 5.94∙× 10−7 | 0.71 | ↑ |
| 60.0784 ([M + H-CH2O]+) | |||||||||
| 74.0927 ([M + H-NH2]+) | |||||||||
| 60.9827 ([M + H-CHO]+) | |||||||||
| 72.0752 ([M + H-H2O]+) | |||||||||
| 6 | 19.0 | C5H9NO2 | Proline * | 115.0629 | 3.5 | 70.0638 ([M + H-H2O-CO]+) | 1.11∙× 10−4 | 0.25 | ↑ |
| 7 | 19.1 | C5H9NO4 | Glutamic acid * | 147.0529 | 2.0 | 84.0429 ([M + H-2H2O-CO]+) | 6.38 × 10−5 | 6.62∙× 10−2 | ↑ |
| 56.0480 ([M + H-2H2O-2CO]+) | |||||||||
| 8 | 19.3 | C6H12N2O4S2 | Cystine * | 240.0215 | 9.6 | 74.0216 ([M + H-C3H7NO2-CH2S2]]) | 1.00 ×∙10−3 | 0.29 | ↑ |
| 120.0109 ([M + H-C3H7NO2S]+) | |||||||||
| 122.0247 ([M + H-C3H5NO2S]+) | |||||||||
| 151.9848 ([M + H-C3H7NO2]+) | |||||||||
| 9 | 19.9 | C9H11NO3 | Tyrosine * | 181.0731 | 4.4 | 91.0501 ([M + H-NH3-H2O-2CO]+) | 2.28∙× 10−2 | 8.27∙× 10−4 | ↑ |
| 136.0711 ([M + H-H2O-CO]+) | |||||||||
| 119.0445 ([M + H-NH3-H2O-CO]+) | |||||||||
| 123.0398 ([M + H-NH3-CH2CO]+) | |||||||||
| 95.0450 ([M + H-NH3-CH2CO-CO]+) | |||||||||
| 10 | 24.6 | C12H23NO7 | 293.1472 | 1.0 | 230.1350 ([M + H-2H2O-CO]+) 258.1301 ([M + H-2H2O]+) | 8.87∙× 10−8 | 0.30 | ↑ | |
| 276.1404 ([M + H-H2O]+) | |||||||||
| 11 | 26.3 | C15H21NO7 | 327.1316 | 0.6 | 310.1226 ([M + H-H2O]+) | 8.51∙× 10−6 | 0.28 | ↑ | |
| 292.1189 ([M + H-2H2O]+) | |||||||||
| 264.1281 ([M + H-H2O-C2H5OH]+) | |||||||||
* Metabolites unequivocally identified with co-injection of the standard solution. ** p-value of Mann Whitney U test < FDR cut-off (0.040). *** ↑: The metabolite (on average) is more abundant in HG vs. NG. ↓: The metabolite (on average) is less abundant in HG vs. NG.